Allarity Therapeutics
Bruce Pratt is a retired individual who has an extensive work experience in the biotechnology and pharmaceutical industry. Bruce has held various roles throughout their career, including VP of Science Development at Genzyme, where they worked from 1988 to 2010. Bruce also served as the COO of Product Development USA at Oncology Venture, where they were responsible for manufacturing and provided scientific and technical due diligence on new product opportunities. Additionally, they worked as a Director of Development at both Lantern Pharma and Oncology Venture, focusing on the development of a precision cancer medicine. Earlier in their career, they worked as a Research Scientist at Collagen Corp/Celtrix Corp. Bruce also has experience as a Principal Advisor at Larta Institute and as a Principal Consultant at BioInnovation Consulting, where they provided guidance on various aspects of strategic and tactical issues for early-stage biotechnology and life science companies.
Bruce Pratt holds a Ph.D. in Developmental Biology from Michigan State University. Bruce also completed their undergraduate studies at Michigan State University, earning a B.S. in Zoology.
This person is not in any offices
Allarity Therapeutics
2 followers
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.